Cerebral Microbleeds

Cerebral microbleeds (CMBs) detected in hemosiderin-sensitive cranial magnetic resonance imaging (MRI) is a common cerebrovascular pathology, which is a risk factor for intracerebral hemorrhage and ischemic stroke in the elderly population. CMBs seen in lobar localization are associated with cerebral amyloid angiopathy (CAA), and those in deep localization are more associated with hypertensive arteriopathy. Population-based studies previously conducted on this subject are limited. Graff-Radford et al. (1) compared the prevalence of CMBs in the normal population and the relationship with beta amyloid burden in positron emission tomography (PET) in their paper published last year in the Journal of Neurology.

For the study, participants without cognitive impairment were randomly selected from among participants of the Mayo Clinic Study of Aging. 3T cranial MRI including T2 gradient echo (GRE)-weighted images was taken for the selected 1215 participants, and 1213 of them underwent amyloid PET imaging and were analyzed.

As a result, the age range of the participants was 60-98 years, the mean age was 74.1 years; 53% were male. The mean age was older (78.7 vs. 72.8 years, p<0.001), male sex [183 (67%) vs. 465 (49%), p<0.001] and hypertension were more frequent [208 (76%) vs. 587 (62%), p<0.001], and amyloid PET involvement was higher [1.68 (0.48) vs. CMBs 1.52 (0.37), p<0.001] in participants with CMBs than in those without CMBs. Participants with CMBs were more likely to develop dementia than those without CMBs [9 (3%) vs. 7 (1%), p=0.001].

It was observed that the frequency of CMBs was 23% in all groups, and increased with age to 39% above 80 years of age.

According to their location, there was only a significant relationship between amyloid PET involvement and the presence of lobar CMBs, but not deep/infratentorial CMBs. In patients with amyloid involvement without lobar CMBs, the etiology was observed to be associated with hypertension. CMBs were more frequently seen in the parietal, occipital, and temporal lobes.

The association of CMBs with age, sex, hypertension, and amyloid load was shown, but no association of CMBs with ApoE ε4 carrier, dyslipidemia, smoking, and diabetes mellitus was found.

This study expanded the findings of previous population-based studies, showing a relationship between global amyloid load and the location of CMBs, and suggested a different underlying pathophysiology for CMBs depending on location. It revealed that there was a relationship between regional lobar amyloid burden and regional CMBs, and the presence of two or more CMBs in temporal, occipital, parietal regions and amyloid burden.

Considering that approximately 37% of patients over eighty years of age have atrial fibrillation, the risk of ischemic stroke, which is an indication of anticoagulation, increases and the number of CMBs associated with amyloid load increases with age. The fact that CMBs constitute a strong risk factor for hemorrhagic stroke also poses a challenge in management in terms of safety of anticoagulation in these patients.

The fact that amyloid load in patients with Alzheimer’s dementia or vascular cognitive impairment is also associated only with lobar CMBs supports the view that CAA causes lobar CMBs.
Consequently, in this population-based study, it was observed that the frequency of CMBs increased with age and that amyloid load was associated with increased frequency of lobar CMBs. The study is important in terms of guiding for identifying individuals at risk of intracerebral bleeding or complications originating from anti-amyloid therapy.

**Ethics**

**Peer-review:** Internally peer-reviewed.

**Financial Disclosure:** The author declared that this study received no financial support.

**Reference**